Publications by authors named "R Tynebor"

Article Synopsis
  • Researchers have developed a new series of positive allosteric modulators (PAMs) targeting muscarinic acetylcholine receptor 4, focusing on 2,3-disubstituted and 2,3,6-trisubstituted compounds.
  • Through iterative libraries, they identified effective substituents that enhanced the potency of these compounds, leading to a selective and brain-penetrant candidate, compound 24.
  • Preclinical tests show that compound 24 can reduce amphetamine-induced hyperactivity in rats and mice, with fewer side effects compared to a nonselective agonist, indicating its potential as a safer treatment option for psychosis.
View Article and Find Full Text PDF

Previous work has suggested that activation of mGlu5 receptor augments NMDA receptor function and thereby may constitute a rational approach addressing glutamate hypofunction in schizophrenia and a target for novel antipsychotic drug development. Here, we report the in vitro activity, in vivo efficacy and safety profile of 5PAM523 (4-Fluorophenyl){(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl}methanone), a structurally novel positive allosteric modulator selective of mGlu5. In cells expressing human mGlu5 receptor, 5PAM523 potentiated threshold responses to glutamate in fluorometric calcium assays, but does not have any intrinsic agonist activity.

View Article and Find Full Text PDF

This manuscript concludes the Structure Activity Relationship (SAR) on the pyridazinone scaffold and identifies a compound with subnanomolar p38α activity and 24h coverage in the rat arthritis efficacy model.

View Article and Find Full Text PDF

Next generation NNRTIs are sought which possess both broad spectrum antiviral activity against key mutant strains and a high genetic barrier to the selection of new mutant viral strains. Pyridones were evaluated as an acyclic conformational constraint to replace the aryl ether core of MK-4965 (1) and the more rigid indazole constraint of MK-6186 (2). The resulting pyridone compounds are potent inhibitors of HIV RT and have antiviral activity in cell culture that is superior to other next generation NNRTI's.

View Article and Find Full Text PDF

The development and synthesis of potent p38α MAP kinase inhibitors containing a pyridazinone platform is described. Evolution of the p38α selective pyridopyridazin-6-one series from the p38α/β dual inhibitor 2H-quinolizin-2-one series will be discussed in full detail.

View Article and Find Full Text PDF